ReviewEClinicalMedicine2025
Rethinking the WHO AWaRe classification: the need for more detailed guidance.
Review in EClinicalMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antimicrobial Consumption and Prescribing Patterns in Hospitalized Children During and After the COVID-19 Pandemic.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The World Health Organization's Access, Watch, and Reserve (AWaRe) classification promotes appropriate antibiotic use and is widely adopted as a global indicator of antimicrobial use (AMU) quality. This paper highlights key limitations of the AWaRe classification system, using Japan as a case study. The global targets for the proportional use of "Access" antibiotics (60%-70%) lack epidemiological justification and may not fully capture regional disease patterns to reflect regional disease patterns. Furthermore, inconsistencies in drug classification and the influence of long-term prescriptions can distort Access category percentages. As most countries do not monitor prescription duration in AMU surveillance, global comparisons using the current AWaRe framework may be misleading. This paper suggests a careful reassessment of AMU surveillance methodology or the AWaRe classification itself to ensure meaningful evaluation of antibiotic stewardship efforts worldwide. Funding: This article was funded by a research grant from the Ministry of Health, Labour and Welfare (JP23HA2002) and JSPS KAKENHI grant number JP23K18396 and the funders did not play any role in writing the manuscript.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.